Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were include...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2018-12, Vol.62 (12)
Main Authors: Cressey, Tim R, Harrison, Linda, Achalapong, Jullapong, Kanjanavikai, Prateep, Patamasingh Na Ayudhaya, Orada, Liampongsabuddhi, Prateung, Siriwachirachai, Thitiporn, Putiyanun, Chaiwat, Suriyachai, Pornnapa, Tierney, Camlin, Salvadori, Nicolas, Chinwong, Dujrudee, Decker, Luc, Tawon, Yardpiroon, Murphy, Trudy V, Ngo-Giang-Huong, Nicole, Siberry, George K, Jourdain, Gonzague
Format: Article
Language:English
Subjects:
Antiviral Agents
Hepatitis B virus
Hepatitis B, Chronic
Infectious Disease Transmission, Vertical
Pharmacology
Tenofovir
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC ]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01686-18